SCHEMBL2653042

SCHEMBL2653042

COCCN1CCN(c2cccc(-n3cnc4cc(CC(=O)OCCO)ccc43)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.42
SRC P12931 4/20 0.42
KDR P35968 1/20 0.41
HPGD P15428 3/20 0.40
ENPP2 Q13822 1/20 0.40
FLT3 P36888 2/20 0.39
NTRK1 P04629 1/20 0.39
RIPK1 Q13546 1/20 0.39
RIPK3 Q9Y572 1/20 0.39
CYP3A4 P08684 1/20 0.39
KCNH2 Q12809 1/20 0.39
LRRK2 Q5S007 1/20 0.39
SLCO1B1 Q9Y6L6 1/20 0.39
KIT P10721 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR1A P08908 1/20 0.38
TMEM97 Q5BJF2 2/20 0.38
SIGMAR1 Q99720 2/20 0.38
GABRP O00591 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652431 0.92 RIPK1 (0.42) FGFR1SRCKDRHPGDENPP2
SCHEMBL2652930 0.86 FGFR1 (0.50) FGFR1HPGDMEN1KMT2A
SCHEMBL2653048 0.85 HPGD (0.40) FGFR1SRCHPGDFLT3RIPK1
SCHEMBL2653965 0.82 FGFR1 (0.56) FGFR1HPGDMEN1KMT2A
SCHEMBL2649765 0.82 HPGD (0.51) HPGDRIPK1RIPK3KMT2A
SCHEMBL2650302 0.82 HPGD (0.50) FGFR1HPGDRIPK1RIPK3
SCHEMBL4704314 0.81 FGFR1 (0.51) FGFR1HPGDMEN1KMT2A
SCHEMBL14852237 0.80 ENPP2 (0.42) FGFR1SRCKDRHPGDENPP2
SCHEMBL2654312 0.80 FGFR1 (0.52) FGFR1SRCHPGDCYP3A4KCNH2
SCHEMBL4702087 0.79 FGFR1 (0.48) FGFR1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP claimed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US claimed
EP-1615896-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2006-01-18 EP claimed
WO-2004089912-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2004-10-21 WO claimed
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP disclosed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US disclosed
EP-1615896-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2006-01-18 EP disclosed
WO-2004089912-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA2, GABRA1, GABRA5 FGFR1 2849/4885SRC 3901/4885KDR 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.